 BOSTON, Oct. 14, 2021 GLOBE NEWSWIRE -- Yumanity Therapeutics NASDAQ: YMTX, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to an employee of non-statutory stock options for the purchase of up to an aggregate of 4,000 shares of Yumanitys common stock. The options will vest over four years, with 25 percent of the shares vesting on the first anniversary of the employees new hire date and the remainder vesting in equal monthly installments over the following three years. The options will have an exercise price of 10.48 per share, which is equal to the closing price of Yumanitys common stock on October 1, 2021, the grant date for the stock options, have a ten-year term and will be subject to the terms and conditions of the Yumanity Therapeutics, Inc. 2021 Inducement Plan and the terms and conditions of a stock option agreement covering the grant. The stock options were granted as inducements material to the employees entering into employment with Yumanity Therapeutics in accordance with Nasdaq Listing Rule 5635c4. 